The pharma major's MD and CEO Subhanu Saxena says the company is aiming at achieving a growth of 70-80 percent growth without making any major acquisitions in the near future.
first published: Aug 27, 2015 09:17 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Stays Below 25,600 Amid Expiry-Led Volatility; Grasim, Hindalco In Focus| Closing Bell Live
Pine Labs’ Rs 3,900 Cr IPO| CEO Amrish Rau On Why The Issue Size Was Cut & The Post-IPO Gameplan
Can Nifty Claw Back Above 25,600 Or Will Sensex Expiry Cap The Upside?| Opening Bell Live
Gold ETFs vs Silver ETFs | Which One Is Your Wealth Buddy?
